In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the Pharmaceuticals industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.

Eli Lilly and Co Background

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Company P/E P/B P/S ROE EBITDA (in billions) Gross Profit (in billions) Revenue Growth
Eli Lilly and Co 134.51 68.82 20.65 19.91% $3.03 $7.57 28.1%
Novo Nordisk A/S 50.13 39.09 18.06 22.01% $28.51 $55.85 36.95%
Johnson & Johnson 30.55 5.56 4.78 5.78% $6.82 $14.6 7.3%
Merck & Co Inc 885.64 8.36 5.25 -3.11% $-0.77 $10.72 5.78%
AstraZeneca PLC 34.75 5.24 4.51 2.52% $2.18 $9.72 7.29%
Novartis AG 24.37 4.38 4.48 19.99% $4.18 $8.75 7.39%
Pfizer Inc 72.41 1.70 2.58 -3.62% $-1.77 $6.69 -41.34%
Sanofi SA 20.59 1.49 2.40 -0.75% $0.42 $8.15 6.5%
Bristol-Myers Squibb Co 13.80 3.66 2.46 6.03% $4.45 $8.73 0.62%
GSK PLC 14.27 5.20 2.32 2.64% $1.16 $5.63 9.16%
Zoetis Inc 35.80 16.63 9.82 10.42% $0.83 $1.49 8.48%
Takeda Pharmaceutical Co Ltd 39.45 1.03 1.68 1.53% $314.89 $731.71 1.33%
Viatris Inc 246.60 0.72 0.96 -3.7% $-0.07 $1.6 -1.0%
Dr Reddy's Laboratories Ltd 20.20 3.93 3.89 5.29% $22.42 $42.2 6.57%
Jazz Pharmaceuticals PLC 19.08 1.94 2.19 2.61% $0.29 $0.9 4.1%
Average 107.69 7.07 4.67 4.83% $27.4 $64.77 4.22%

By closely studying Eli Lilly and Co, we can observe the following trends:

  • The Price to Earnings ratio of 134.51 for this company is 1.25x above the industry average, indicating a premium valuation associated with the stock.

  • With a Price to Book ratio of 68.82, which is 9.73x the industry average, Eli Lilly and Co might be considered overvalued in terms of its book value, as it is trading at a higher multiple compared to its industry peers.

  • With a relatively high Price to Sales ratio of 20.65, which is 4.42x the industry average, the stock might be considered overvalued based on sales performance.

  • The company has a higher Return on Equity (ROE) of 19.91%, which is 15.08% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.

  • The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $3.03 Billion is 0.11x below the industry average, suggesting potential lower profitability or financial challenges.

  • The gross profit of $7.57 Billion is 0.12x below that of its industry, suggesting potential lower revenue after accounting for production costs.

  • With a revenue growth of 28.1%, which surpasses the industry average of 4.22%, the company is demonstrating robust sales expansion and gaining market share.

Debt To Equity Ratio

debt to equity

The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

In light of the Debt-to-Equity ratio, a comparison between Eli Lilly and Co and its top 4 peers reveals the following information:

  • Compared to its top 4 peers, Eli Lilly and Co has a higher debt-to-equity ratio of 2.34, indicating a higher level of debt financing.

  • This higher debt proportion can expose the company to increased financial risk and potential challenges.

Key Takeaways

For Eli Lilly and Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all high compared to its peers, indicating potentially overvalued stock. On the other hand, the high ROE and revenue growth suggest strong profitability and future prospects. However, the low EBITDA and gross profit may raise concerns about operational efficiency and cost management.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMarketsTrading IdeasBZI-IA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!